YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Vortex to accelerate anti-infective research at the Institute for Molecular Bioscience at the University of Queensland, Australia

Dotmatics data analysis and visualisation tool proven essential in Prof. Cooper's team's quest for finding new 'superbug' antibiotics

BISHOP'S STORTFORD, UK - Aug 20, 2014 - ~~Dotmatics, a leading provider of scientific informatics solutions and services, announced today that Prof. Cooper’s renowned Medicinal Chemistry and Drug Development research group at the Institute for Molecular Bioscience, University of Queensland has deployed Vortex, Dotmatics’ leading scientific intelligence and analytics solution, to assist with their innovative research in anti-infective therapies.

Infectious disease remains the second leading cause of death globally. The increase in multidrug-resistant (MDR) bacteria and the decline in effective therapies have resulted in ‘the superbug crisis.’ Research conducted by Prof. Cooper’s team has led to the discovery of several drug candidates against anti-infective diseases. The team is also spearheading a global initiative, Worldwide Antibiotic Discovery Initiative for the discovery and development of new therapies against multidrug-resistant (MDR) microorganisms. This complex research encompasses the analysis of large amounts of biological and chemical data. Dotmatics’ Vortex provides Prof. Cooper’s team with an essential tool to perform complex data mining, analysis and visualisation, enabling the scientists to find unique trends and identify lead compounds in an effective way.

 “We have large data sets generated from our high-throughput antimicrobial screening facility and multiple collaborative development projects, as well as the integration of publicly available data. Statistical analysis and visualisation of the data thereby plays a crucial role in the decision making process of selecting and progressing drug candidates,” said Prof. Cooper. “The Dotmatics Platform has an important role in the team as it assists the decision making process by providing a comprehensive and interactive visualisation tool to our medicinal chemists.”

“We are very pleased to continue our expansion in Australia and proud to have been selected by Prof. Cooper’s team to provide solutions to assist with his complex research of anti-infective drug candidates,” said Dr Mike Hartshorn, CSO at Dotmatics. “We invest strongly in developing great informatics solutions for the scientific community and are thrilled to learn that world class researchers across all continents are using Vortex and the Dotmatics Platform to accelerate their studies.”

About Dotmatics: Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile scientific environments. The company provides solutions to several vertical markets, including the pharmaceutical, biotechnology, academia, food and beverage, oil and gas and agrochemical industries. Dotmatics’ enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. Dotmatics solutions are available for local or cloud deployment and they are supported on Microsoft Windows, Mac OS X and Linux.  A privately owned company, Dotmatics was founded in 2005 and their headquarters is based south of Cambridge in the UK.


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.